Moolec Science (MLEC) has entered into a landmark agreement to merge with Bioceres Group in an all-stock transaction. Under the Business Combination Agreement (BCA), signed on April 17, several stakeholders will consolidate their interests in Bioceres Group, Nutrecon, and Gentle Technologies. This consolidation will result in an expanded corporate structure with Moolec as the parent company.
Moolec plans to issue up to 87 million newly minted shares and 5 million warrants to the shareholders involved in the deal. Following this merger, Moolec is set to enhance its position in the agricultural sector by focusing on seed and microbe modification to optimize land and water utilization while supporting human health advancements. The companies involved bring a robust catalog of over 800 patents and more than 550 product registrations, collectively generating over half a billion dollars in sales across 50 countries.
The agreement has received unanimous approval from the boards of all parties involved and is anticipated to close in the second quarter of 2025, pending regulatory approvals and shareholder consent. Approximately 70% of Moolec's shareholders initially proposed the transaction, suggesting likely strong support for its completion.
As part of the transaction, Bioceres Group shareholders will exchange their holdings for up to 80,590,280 shares of Moolec. Additionally, shareholders of Nutrecon and Gentle Technologies will swap their ownership for 6,475,000 Moolec shares and 5 million warrants, priced at $2 each. These terms offer a significant premium over Moolec's current stock value, positioning the company for substantial growth in the agricultural sector.
Gaston Paladini will step down as CEO and Chairman following an Extraordinary General Meeting on April 22, marking a leadership transition as Moolec embarks on this strategic growth phase.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Bioceres Crop Solutions Corp (BIOX, Financial) is $7.88 with a high estimate of $9.00 and a low estimate of $6.50. The average target implies an upside of 90.22% from the current price of $4.14. More detailed estimate data can be found on the Bioceres Crop Solutions Corp (BIOX) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Bioceres Crop Solutions Corp's (BIOX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bioceres Crop Solutions Corp (BIOX, Financial) in one year is $10.62, suggesting a upside of 156.52% from the current price of $4.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bioceres Crop Solutions Corp (BIOX) Summary page.
